Entera Bio: Nearly triples on positive interim data from osteoporosis treatment study

Entera Bio

11/03/2021 14:42

** U.S.-listed shares of Israel-based drugmaker  ENTX.O 
rise ~181%, or nearly three times, to $4.50
    ** Co reports positive 3-month bone biomarker data from
ongoing mid-stage trial of its osteoporosis treatment candidate,
EB613  urn:newsml:reuters.com:*:nGNX6dQ0fY
    ** As per the data, patients receiving 2.5 mg dose of EB613
met main goal of significant rate of new bone formation 
    ** The six-month study, being conducted in postmenopausal
female subjects with osteoporosis in Israel, is testing safety
of EB613 and identifying best dose regimen for a potential
late-stage trial
    ** Osteoporosis is a bone disease that causes loss of bone
density, increasing the risk of fractures
    ** ENTX expects to report final results from this trial in
Q2 of 2021
    ** Including session's gain, stock up ~48% this year

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))